Background: Allergic contact dermatitis is a chronic inflammatory T cell mediated disease that can be recalcitrant to existing treatments. Ustekinumab is a monocloncal antibody blocking IL-12 and IL-23, shown to be effective and safe for patients with psoriasis. Despite both IL-12 and IL-23 involvement in contact allergy, the effect of Ustekinumab on allergic contact dermatitis has not been reported.
Objectives: To evaluate the clinical effect of Ustekinumab in patients with allergic contact dermatitis.
Methods: A retrospective, case cohort study of patients with allergic contact dermatitis treated with Ustekinumab in our department.
Results: Five patients had been treated with Ustekinumab for allergic contact dermatitis, with limited effect.
Conclusion: Our observation suggests that, although theoretically plausible, Ustekinumab does not seem to be a valuable therapeutic approach for chronic allergic contact dermatitis.
© 2011 John Wiley & Sons A/S.